Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

PHASE3RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2029

Conditions
Tyrosine Kinase InhibitorsChronic Myeloid Leukemia
Interventions
DRUG

treatment of TKI in CML

continued treatment with TKI at randomization a then stopped treatment 12 months after randomization

Trial Locations (20)

Unknown

RECRUITING

Chu Angers, Angers

ACTIVE_NOT_RECRUITING

Ch Annecy, Annecy

RECRUITING

Ch Bayonne, Bayonne

RECRUITING

Chu Brest, Brest

RECRUITING

CH Brive la Gaillarde, Brive-la-Gaillarde

ACTIVE_NOT_RECRUITING

Ch Chambery, Chambéry

RECRUITING

CHI Creteil, Créteil

RECRUITING

Ch La Rochelle, La Rochelle

RECRUITING

Chu Lille, Lille

RECRUITING

CHU Limoges, Limoges

RECRUITING

Centre Léon Bérard, Lyon

RECRUITING

Ch Mont de Marsan, Mont-de-Marsan

ACTIVE_NOT_RECRUITING

Chu Nancy, Nancy

RECRUITING

Chu Nantes, Nantes

ACTIVE_NOT_RECRUITING

Hopital Prive Du Confluent, Nantes

RECRUITING

Ch Perigueux, Périgueux

RECRUITING

Chu Poitiers, Poitiers

RECRUITING

Oncopole Toulouse, Toulouse

RECRUITING

Chu Tours, Tours

RECRUITING

CH Versailles, Versailles

All Listed Sponsors
lead

Poitiers University Hospital

OTHER